ALNY SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 29, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 30, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 30, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 12, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 30, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Alnylam Pharmaceuticals Announces Executive Departure and $1.0 Billion Share Repurchase Program

Nov 5, 2026

8-K

Alnylam Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Highlights

Oct 29, 2026

8-K

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Pipeline Progress

Jul 30, 2026

8-K

Alnylam Pharmaceuticals Expands Board of Directors and Reports Annual Meeting Results

May 27, 2026

8-K

Alnylam Pharmaceuticals Reports Strong Q1 2026 Financial Results and Pipeline Progress

Apr 30, 2026

8-K

Alnylam Grants CEO Yvonne Greenstreet Special Performance-Based Equity Award

Mar 4, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

5,000,000 Shares

Jan 15, 2019

424B5

5,000,000 Shares

Jan 14, 2019

424B5

Common Stock

Nov 14, 2017

424B5

Common Stock

Nov 13, 2017

424B5

5,000,000 Shares

May 25, 2017

424B5

5,000,000 Shares

May 23, 2017

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Feb 12, 2026

S-8

Registration

Feb 23, 2023

S-8

Registration

Feb 11, 2021

S-3ASR

963,486 Shares of Common Stock

Jun 5, 2020

S-8

Registration

Feb 13, 2020

S-8 POS

Registration

Aug 2, 2018

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 6, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 6, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 4, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Mar 24, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Mar 24, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Mar 14, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

SCHEDULE 13G

VANGUARD PORTFOLIO MANAGEMENT LLC (Filed by)

Oct 30, 2026

SUPRAN BRYAN (Reporting)

Oct 6, 2026

144

Form 144 - Report of proposed sale of securities

Oct 2, 2026

Greenstreet Yvonne (Reporting)

Sep 22, 2026

PYOTT DAVID E I (Reporting)

Jun 3, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Jun 17, 2025

CORRESP

Form CORRESP - Correspondence

May 22, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 9, 2025

LETTER

Form UPLOAD - SEC-generated letter

Sep 25, 2024

CORRESP

Form CORRESP - Correspondence

Aug 22, 2024

LETTER

Form UPLOAD - SEC-generated letter

Aug 12, 2024

Alnylam Pharmaceuticals, Inc. ALNY · SEC Filings